Acrivon Therapeutics, Inc. ACRV 深 沪

Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 3.92 percent increase over losses of $(0.51) per share

05-14 04:24

Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics

04-18 04:03

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

04-17 20:00

Acrivon Therapeutics Q4 net loss narrows as expenses fall

Acrivon Therapeutics Q4 net loss narrows as expenses fall Overview US biopharma firm's Q4 net loss narrowed from prior year as expenses declined Research and development and administrative costs fell, driven by fewer milestones and lower personnel costs Company expects cash and investments to fund o

03-19 19:28

Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.57) by 13.58 percent. This is a 18.33 percent increase over losses of $(0.60) per share

03-19 19:23

BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million

BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million Mar 19 (Reuters) - Acrivon Therapeutics, Inc Q4 operating expenses USD 20.116 million. Q4 basic EPS USD -0.49 Q4 net income USD -18.985 million

03-19 19:22

Acrivon Therapeutics To Reveal Pre-Clinical AP3 Data At The 2026 AACR Annual Meeting

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ACR-2316,

03-18 05:57

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Acrivon Therapeutics announced three poster presentations at the AACR Annual Meeting 2026, highlighting promising results from their precision medicines. ACR-368, a CHK1/2 inhibitor, showed potent synergy with Topo1 inhibitors, commonly used in ADCs, overcoming resistance mechanisms. ACR-2316, a WEE1/PKMYT1 inhibitor, demonstrated complete tumor regression and durable immune protection when combined with anti-PD-L1 checkpoint inhibition in precli...

03-17 21:54

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

Acrivon Therapeutics has received CLIA certification for its internal laboratory in Watertown, Massachusetts, enabling patient testing and companion diagnostic development. The lab enhances the company's capabilities in precision medicine, biomarker discovery, and therapeutic development, while improving efficiency and reducing reliance on external partners. Acrivon is leveraging its proprietary Generative Phosphoproteomics AP3 platform to advanc...

02-18 13:00

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

Acrivon Therapeutics will present interim clinical data for ACR-368, a precision medicine targeting endometrial cancer, at the ESGO 27th Annual Congress in Copenhagen. Dr. Panagiotis Konstantinopoulos, a global KOL, will highlight the data from the Phase 2b study, showcasing the drug's potential in a high unmet need population. The presentation is scheduled for Feb 27, 2026. Acrivon's proprietary Generative Phosphoproteomics AP3 platform drives i...

01-23 13:11